Breast Cancer
Conditions
Keywords
Locally recurrent breast cancer, metastatic breast cancer
Brief summary
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
Interventions
DRUGE7389
1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Sponsors
Eisai Limited
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis. 2. Patients with locally recurrent or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent and/or metastatic disease. Prior therapy must be documented by the following criteria prior to entry onto study: * Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment with any of these agents is not required if they are contraindicated for a certain patient. * One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least 2 must have been given for relapsed or metastatic disease. * Patients must have proved refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy. * Patients with Human Epidermal Growth Factor 2 (HER2/neu) positive tumors may additionally have been treated with trastuzumab. * Patients may have additionally been treated with anti-hormonal therapy. 3. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy \<= Grade 2 and alopecia. 4. Age \>= 18 years. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 6. Life expectancy of \>= 3 months. 7. Adequate renal function as evidenced by serum creatinine \<= 2.0 mg/dL or calculated creatinine clearance \>= 40 mL/min per the Cockcroft and Gault formula. 8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L, hemoglobin \>= 10.0 g/dL (a hemoglobin \<10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count \>= 100 x 10\^9/L. 9. Adequate liver function as evidenced by bilirubin \<= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \<= 3 x ULN (in the case of liver metastases \<= 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. In case alkaline phosphatase is \>3 x ULN (in absence of liver metastases) or \> 5 x ULN (in presence of liver metastases) AND patient is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. 10. Patients willing and able to comply with the study protocol for the duration of the study. 11. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
Exclusion criteria
1. Patients who have received any of the following treatments within the specified period before E7389 or TPC treatment start: * chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks. * any investigational drug within four weeks. 2. Radiation therapy encompassing \> 30% of marrow. 3. Prior treatment with mitomycin C or nitrosourea. 4. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen. 5. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain scan performed during screening to a prior scan performed at least 4 weeks earlier. 6. Patients with meningeal carcinomatosis. 7. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy if randomized to E7389 are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored. 8. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. 9. Severe/uncontrolled intercurrent illness/infection. 10. Significant cardiovascular impairment (history of congestive heart failure \> New York Heart Association grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia). 11. Patients with organ allografts requiring immunosuppression. 12. Patients with known positive HIV status. 13. Patients who have had a prior malignancy, other than previous breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated \>= 5 years previously with no subsequent evidence of recurrence. 14. Patients with pre-existing neuropathy \> Grade 2. 15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative. 16. Patients who participated in a prior E7389 clinical trial whether or not E7389 was received. 17. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From date of randomization until death from any cause | Defined as the time from the date of randomization until the date of death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival. | Until disease progression or death. | Measured using Response Evaluation Criteria in Solid Tumors (RECIST) and defined as the time from the date of randomization until progressive disease or death from any cause in the absence of of progressive disease. |
| Best Overall Response | Until Day 30 or every 3 months during Follow-up period for patients who complete study without PD. | Measured by RECIST criteria and defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions). |
| Duration of Response. | From first documented CR or PR until disease progression or death. | As measured by RECIST criteria and defined as the time from the first documented CR or PR until disease progression or death from any cause. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From start of study drug administration up to 30 days after the last dose of study drug (approximately up to 42 months) | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Hungary, Italy, Poland, Russia, South Africa, Spain, Switzerland, United States
Participant flow
Recruitment details
This study was recruited at 135 centers in 19 countries during the period of Nov 2006 to May 2009.
Participants by arm
| Arm | Count |
|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 Eribulin Mesylate 1.4 mg/kg\^2 on Days 1 and 8 | 508 |
| Treatment of Physician's Choice Treatment of Physician's Choice | 254 |
| Total | 762 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Administrative | 6 | 9 |
| Overall Study | Adverse Event | 50 | 24 |
| Overall Study | Clinical Progression | 61 | 36 |
| Overall Study | Death | 3 | 2 |
| Overall Study | Physician Decision | 18 | 13 |
| Overall Study | Progressive Disease | 336 | 153 |
| Overall Study | Withdrawal by Subject | 10 | 7 |
Baseline characteristics
| Characteristic | Treatment of Physician's Choice | Total | Eribulin Mesylate 1.4 mg/kg^2 |
|---|---|---|---|
| Age, Continuous | 55.9 years STANDARD_DEVIATION 10.43 | 55.2 years STANDARD_DEVIATION 10.37 | 54.8 years STANDARD_DEVIATION 10.34 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 5 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 14 Participants | 34 Participants | 20 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 20 Participants | 15 Participants |
| Race (NIH/OMB) White | 233 Participants | 703 Participants | 470 Participants |
| Sex: Female, Male Female | 254 Participants | 762 Participants | 508 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 497 / 503 | 230 / 247 |
| serious Total, serious adverse events | 130 / 503 | 64 / 247 |
Outcome results
Primary
Overall Survival
Defined as the time from the date of randomization until the date of death from any cause.
Time frame: From date of randomization until death from any cause
Population: Intent to Treat
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 | Overall Survival | 399 Days |
| Treatment of Physician's Choice | Overall Survival | 324 Days |
Secondary
Best Overall Response
Measured by RECIST criteria and defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
Time frame: Until Day 30 or every 3 months during Follow-up period for patients who complete study without PD.
Population: Response Evaluable Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Objective Response Rate (CR+PR) | 12.2 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Not Evaluable | 2.6 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Stable Disease | 44.4 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Complete Response | 0.6 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Progressive Disease | 40.6 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Unknown | 0.2 Percent of Participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Best Overall Response | Partial Response | 11.5 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Unknown | 0 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Progressive Disease | 49.1 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Not Evaluable | 1.4 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Objective Response Rate (CR+PR) | 4.7 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Complete Response | 0 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Partial Response | 4.7 Percent of Participants |
| Treatment of Physician's Choice | Best Overall Response | Stable Disease | 44.9 Percent of Participants |
Secondary
Duration of Response.
As measured by RECIST criteria and defined as the time from the first documented CR or PR until disease progression or death from any cause.
Time frame: From first documented CR or PR until disease progression or death.
Population: Response Evaluable Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 | Duration of Response. | 128 Days |
| Treatment of Physician's Choice | Duration of Response. | 205 Days |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From start of study drug administration up to 30 days after the last dose of study drug (approximately up to 42 months)
Population: The safety analysis set was all participants who were randomized and who received at least a partial dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAE | 497 participants |
| Eribulin Mesylate 1.4 mg/kg^2 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAE | 130 participants |
| Treatment of Physician's Choice | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAE | 230 participants |
| Treatment of Physician's Choice | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAE | 64 participants |
Secondary
Progression-Free Survival.
Measured using Response Evaluation Criteria in Solid Tumors (RECIST) and defined as the time from the date of randomization until progressive disease or death from any cause in the absence of of progressive disease.
Time frame: Until disease progression or death.
Population: Intent to Treat
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Eribulin Mesylate 1.4 mg/kg^2 | Progression-Free Survival. | 113 Days |
| Treatment of Physician's Choice | Progression-Free Survival. | 68 Days |